Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that v::NTRK1 status confers therapeutic sensitivity to Larotrectinib in patients with Any solid tumor.
This statement is based on a regulatory approval from the Health Canada:
VITRAKVI (larotrectinib) is indicated for the treatment of adult and pediatric patients with solid tumours that have a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion without a known acquired resistance mutation.